Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 105
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Kudoh, Chiaki Arita, Ryutaro Honda, Mitsuru Kishi, Taichi Komatsu, Yasuhiro Asou, Hiroaki and Mimura, Masaru 2016. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation. Psychogeriatrics, Vol. 16, Issue. 2, p. 85.


    Paholpak, Pongsatorn and Mendez, Mario F. 2016. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry.


    Yoon, Bora Yang, Dong Won Hong, Yun Jeong Choi, Seong Hye Park, Sun Ah Park, Hee Kyung Kim, Yong Duk Shim, Yong S. and Seo, Sang Won 2016. Differences in Depressive Patterns According to Disease Severityin Early-Onset Alzheimer’s Disease. Journal of Alzheimer's Disease, Vol. 52, Issue. 1, p. 91.


    Atri, Alireza and Stern, Theodore A. 2015. Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease. Psychiatric Annals, Vol. 45, Issue. 7, p. 354.


    Giannopoulos, Phillip F. and Praticò, Domenico 2015. Diet and Nutrition in Dementia and Cognitive Decline.


    Jacquin-Piques, Agnès Sacco, Guillaume Tavassoli, Neda Rouaud, Olivier Bejot, Yannick Giroud, Maurice Robert, Philippe Vellas, Bruno and Bonin-Guillaume, Sylvie 2015. Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home. Journal of Alzheimer's Disease, Vol. 49, Issue. 3, p. 671.


    Panza, Francesco Solfrizzi, Vincenzo Seripa, Davide Imbimbo, Bruno P Santamato, Andrea Lozupone, Madia Prete, Camilla Greco, Antonio Pilotto, Alberto and Logroscino, Giancarlo 2015. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opinion on Pharmacotherapy, Vol. 16, Issue. 17, p. 2581.


    Salamone, John D. Koychev, Ivan Correa, Mercè and McGuire, Philip 2015. Neurobiological basis of motivational deficits in psychopathology. European Neuropsychopharmacology, Vol. 25, Issue. 8, p. 1225.


    Siarkos, Kostas T. Katirtzoglou, Everina A. Politis, Antonios M. and Smith, Gwenn 2015. A Review of Pharmacological Treatments for Depression in Alzheimer’s Disease. Journal of Alzheimer's Disease, Vol. 48, Issue. 1, p. 15.


    Weiser, Mark and Garibaldi, George 2015. Quantifying motivational deficits and apathy: A review of the literature. European Neuropsychopharmacology, Vol. 25, Issue. 8, p. 1060.


    Pan, Weidong Wang, Qiudong Kwak, Shin Song, Yu Qin, Baofeng Wang, Mingzhe and Yamamoto, Yoshiharu 2014. Shen-Zhi-Ling Oral Liquid Improves Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease. Evidence-Based Complementary and Alternative Medicine, Vol. 2014, p. 1.


    Song, In-Uk Chung, Sung-Woo and Chung, Yong-An 2014. Efficacy of an NMDA receptor antagonist for Parkinson's disease dementia: A brain perfusion SPECT study. International Journal of Imaging Systems and Technology, Vol. 24, Issue. 4, p. 326.


    Targum, Steven D. Fava, Maurizio Alphs, Larry D. Lynn Starr, H. Wessel, Thomas C. and Hilt, Dana C. 2014. Fatigue across the CNS spectrum: a clinical review. Fatigue: Biomedicine, Health & Behavior, Vol. 2, Issue. 4, p. 231.


    Tourian, Leon Margolese, Howard C. and Gauthier, Serge 2014. Donepezil-Associated Mania in Two Patients Who Were Using Donepezil Without a Prescription. Journal of Clinical Psychopharmacology, Vol. 34, Issue. 6, p. 753.


    van der Linde, Rianne M. Dening, Tom Matthews, Fiona E. and Brayne, Carol 2014. Grouping of behavioural and psychological symptoms of dementia. International Journal of Geriatric Psychiatry, Vol. 29, Issue. 6, p. 562.


    Ballard, Clive and Corbett, Anne 2013. Agitation and aggression in people with Alzheimerʼs disease. Current Opinion in Psychiatry, Vol. 26, Issue. 3, p. 252.


    Cheewakriengkrai, Laksanun and Gauthier, Serge 2013. A 10-year perspective on donepezil. Expert Opinion on Pharmacotherapy, Vol. 14, Issue. 3, p. 331.


    Drye, Lea T. Scherer, Roberta W. Lanctôt, Krista L. Rosenberg, Paul B. Herrmann, Nathan Bachman, David and Mintzer, Jacobo E. 2013. Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia: The Apathy in Dementia Methylphenidate Trial (ADMET). The American Journal of Geriatric Psychiatry, Vol. 21, Issue. 6, p. 549.


    Fu, Zheng Li, Xue Miao, Yipu and Merz, Kenneth M. 2013. Conformational Analysis and Parallel QM/MM X-ray Refinement of Protein Bound Anti-Alzheimer Drug Donepezil. Journal of Chemical Theory and Computation, Vol. 9, Issue. 3, p. 1686.


    Herrmann, Nathan Gauthier, Serge Boneva, Neli and Lemming, Ole Michael 2013. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. International Psychogeriatrics, Vol. 25, Issue. 06, p. 919.


    ×

Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease

  • Serge Gauthier (a1), Howard Feldman (a2), Jane Hecker (a3), Bruno Vellas (a4), David Ames (a5), Ponni Subbiah (a6), Edward Whalen (a7) and Birol Emir (a8)
  • DOI: http://dx.doi.org/10.1017/S104161020200858X
  • Published online: 01 December 2002
Abstract

Objective: This subanalysis of a large, double-blind, placebo-controlled trial examined the prevalence of behavioral symptoms in moderate to severe Alzheimer's disease (AD), and the effect of treatment with donepezil. Methods: Two hundred ninety patients with moderate to severe AD (standardized Mini-Mental State Examination scores 5–17) were randomized to receive 24 weeks of once-daily doses of donepezil 5 mg/day for 28 days, and 10 mg/day thereafter per the clinician's judgment (n = 144), or placebo (n = 146). The outcome measure of interest was the 12-item Neuropsychiaric Inventory (NPI). Results: Baseline demographics were similar between the treatment groups. Least squares mean (± SE) baseline NPI 12-item total scores were 19.55 ± 1.48 and 19.30 ± 1.45, respectively. At baseline, the most common symptoms were apathy/indifference (67%), aberrant motor behavior (53%), depression/dysphoria (52%), anxiety (49%), and agitation/aggression (45%). NPI individual item change from baseline scores at Week 24 using a last observation carried forward (LOCF) analysis showed benefits with donepezil treatment compared with placebo for all items, with significant treatment differences for depression/dysphoria, anxiety, and apathy/indifference (p < .05). Symptoms present at baseline that improved significantly for donepezil- compared with placebo-treated patients at Week 24 LOCF included anxiety, apathy/indifference, and irritability/lability (p < .05). When patients who were not receiving psychoactive medications at baseline were analyzed separately, significant improvements in NPI 12-item total score were observed with donepezil compared with placebo at most visits and at Week 24 LOCF (p < .05). Conclusions: Behavioral symptoms of the magnitude observed in this moderate to severe AD population improved with donepezil.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: